SynlogicSYBX
About: Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
Employees: 1
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
6% more funds holding
Funds holding: 16 [Q3] → 17 (+1) [Q4]
0.53% less ownership
Funds ownership: 58.34% [Q3] → 57.81% (-0.53%) [Q4]
7% less capital invested
Capital invested by funds: $10.2M [Q3] → $9.46M (-$714K) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for SYBX.
Financial journalist opinion
